查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093165

灰指甲治療市場－2026-2032年全球市場預測

Onychomycosis Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，灰指甲治療市場將成長至 71.7 億美元，複合年成長率為 7.68%。

主要市場統計數據
基準年 2025 42.7億美元
預計年份：2026年 45.7億美元
預測年份 2032 71.7億美元
複合年成長率 (%) 7.68%

灰指甲的治療仍然是皮膚科、足病科和基層醫療中最常見的指甲疾病之一，因此其策略意義日益凸顯。此病通常與皮癬菌、酵母菌和非皮癬菌真菌有關，據報道，老年人、糖尿病患者、免疫力缺乏患者、運動員以及患有周圍血管疾病或慢性指甲外傷的人群中發病率較高。如不及時治療，甲癬可導致疼痛、指甲畸形、繼發性細菌感染、運動功能障礙和生活品質下降，因此，準確診斷、病原體鑑定、患者風險分層以及治療依從性在臨床管理中變得愈發重要。

目前治療甲癬的方法包括口服抗真菌藥物、外用抗真菌溶液和塗料、機械清創、特定情況下可採用雷射治療等器械輔助治療，以及旨在提高藥物對指甲滲透性和改善臨床療效的聯合治療。雖然口服替比萘芬和Itraconazole仍然是廣泛使用的全身性治療方案，但外用藥物在輕度至中度病例、全身性治療禁忌症患者以及長期維持治療中發揮重要作用。市場需求受到以下因素的影響：更安全的治療方法、更短的療程、更高的真菌學治癒率、更低的復發率以及更高的患者遵守用藥。

甲癬治療前景的變革性轉變。

甲癬的治療正在重新定義，更加重視診斷的準確性、以患者為中心的護理以及考慮抗藥性的處方。除了傳統的經驗性治療外，氫氧化鉀顯微鏡檢查、真菌培養、過碘酸雪夫染色組織病理學檢查以及分子診斷（如有條件）等確診性檢查的應用也日益增加。這項轉變意義重大，因為甲癬的症狀可能與乾癬、外傷性甲改變、扁平苔癬和其他非真菌性疾病相似，因此在開始長期抗真菌治療之前，準確診斷至關重要。

人工智慧對甲癬治療的累積影響

人工智慧 (AI) 正透過輔助診斷、基於影像的分診、最佳化工作流程和藥物依從性管理，逐步影響甲癬的治療。 AI 驅動的皮膚科工具可以透過分析指甲影像來輔助臨床醫生識別與真菌感染疾病相符的模式，但由於僅憑臨床觀察不足以確診，因此仍需進行確診性檢測。在遠距皮膚科和數位化足病診療流程中，AI 可以幫助確定病例優先順序、識別高風險患者，並在趾甲再生所需的漫長治療期內遠端監測指甲狀況的改善情況。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

在亞太地區，由於老年人口眾多、多個國家灰指甲負擔沉重、氣候潮濕有利於真菌生長，以及都市區皮膚科和足病科服務的可及性提高，甲癬的治療需求顯著。此外，該地區各國遠距遠端醫療和零售藥局的普及可能有助於早期就診，但同時也可能增加診斷管理的需求，從而減少抗真菌藥物的不當使用。北美地區擁有完善的皮膚科、足病科和基層醫療保健體系，老年人口眾多，糖尿病患病率高，且人們對指甲和足部護理的意識普遍較高。雖然處方箋和口服藥物、診斷測試和專科會診的可近性相對較好，但對於全身性抗真菌藥物的使用，安全性監測和藥物交互作用管理仍然至關重要。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東南亞國協，由於熱帶潮濕氣候、快速都市化、不斷擴張的藥房網路以及都市區皮膚科醫生就診機會的差異，甲癬的治療格局呈現出多樣化的特徵。儘管公共衛生工作的重點通常放在傳染病和慢性病上，但灰指甲、糖尿病護理和足部健康之間的重疊性為將甲癬篩檢納入更廣泛的基層醫療和足病服務提供了機會。在海灣合作理事會（GCC）國家，由於糖尿病患病率高、私立醫療保健服務日益普及、某些市場醫療旅遊的活性化以及對包括器械輔助指甲護理和美甲護理解決方案在內的先進皮膚科服務的需求，甲癬管理的重要性日益凸顯。

主要甲癬治療市場的關鍵國家/地區特定洞察

在美國，甲癬的治療環境已較為成熟，這得益於廣泛的皮膚科和足病科醫療網路、較高的糖尿病患病率以及口服和外用抗真菌藥物的普及；然而，費用、用藥依從性和復發率仍然是重要的障礙。加拿大也面臨類似的臨床挑戰，其基層醫療參與度高，並重視對老年患者和服用多種藥物患者的用藥安全監測。在墨西哥和巴西，由於氣候、人口規模、糖尿病負擔以及專科醫療服務可近性的差異，甲癬的治療需求巨大，因此，準確診斷、降低治療成本以及在藥房進行宣傳活動尤為重要。

針對甲癬（指甲真菌感染）治療，為業界領導者提供的實用建議

業界領導者應優先考慮以實證醫學為基礎的甲癬治療方案，該方案應結合準確診斷、選擇合適的抗真菌藥物、患者教育和預防復發。尤其重要的是，應加強確診檢測的可及性，因為指甲畸形並非總是由真菌引起，不必要的抗真菌藥物使用會引發不必要的安全性和合理用藥問題。治療方案應包含明確的指南，包括口服治療的監測、局部用藥方法、指甲再生的預期時間，以及即使症狀改善緩慢也必須完成治療的重要性。

灰指甲治療調查方法

本執行摘要採用系統性的二手調查方法，利用檢驗的臨床、監管和公共衛生資訊來源編寫而成。評估內容涵蓋皮膚病學和感染疾病指南、同行評審的醫學文獻、藥理學參考資料、糖尿病和老齡化社會相關的公共衛生數據，以及已確立的抗真菌藥物治療、診斷方法、復發和風險因素方面的臨床研究結果。此外，還整合了來自已記錄的醫療基礎設施特徵、疾病風險模式、人口統計指標以及與甲癬診斷和治療相關的可及性因素的區域、人群和國家特定見解。

結論：甲癬實證治療的進展

灰指甲的治療正朝著更精準、以患者為中心和技術驅動的方向發展。準確診斷仍然是有效治療的基礎，口服抗真菌藥物、局部用藥、清創術和聯合治療繼續根據感染嚴重程度、安全性以及用藥依從性等因素，滿足患者的多樣化需求。人工智慧、遠端醫療和數位化用藥依從性工具的日益普及有望改善醫療服務，但這些技術只有在與實驗室驗證和臨床醫生監督相結合時才能發揮最大價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：灰指甲治療市場：依藥物類別分類

  • 唑類藥物
  • Allylamines基

第8章：灰指甲治療市場：依治療類型分類

  • 局部治療
  • 口服療法
  • 聯合治療

第9章：灰指甲治療市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第10章：灰指甲治療市場：以劑型分類

  • 奶油
  • 凝膠
  • 指甲油
  • 解決方案
  • 片劑和膠囊

第11章：灰指甲治療市場：依疾病嚴重程度分類

  • 輕度至中度
  • 復發
  • 嚴重

第12章：灰指甲治療市場：依年齡層別分類

  • 18至65歲
  • 65歲或以上
  • 18歲以下

第13章灰指甲治療市場：依治療環境分類

  • 居家照護
  • 住院病人
  • 門診治療

第14章：灰指甲治療市場：依分銷管道分類

  • 離線
  • 線上

第15章：灰指甲治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第16章：灰指甲治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第17章：灰指甲治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第18章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Galderma SA
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals, Inc.
  • Kaken Pharmaceutical Co., Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Moberg Pharma AB
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
  • Zydus Lifesciences Limited
Product Code: MRR-FD3F12D54166

The Onychomycosis Treatment Market is projected to grow by USD 7.17 billion at a CAGR of 7.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.27 billion
Estimated Year [2026] USD 4.57 billion
Forecast Year [2032] USD 7.17 billion
CAGR (%) 7.68%

Onychomycosis treatment is gaining strategic relevance as fungal nail infections remain among the most common nail disorders seen in dermatology, podiatry, and primary care. The condition is frequently associated with dermatophytes, yeasts, and non-dermatophyte molds, with higher prevalence reported in older adults, people with diabetes, immunocompromised patients, athletes, and individuals with peripheral vascular disease or chronic nail trauma. Clinical management increasingly depends on accurate diagnosis, organism identification, patient risk stratification, and treatment adherence, as untreated disease can contribute to pain, nail dystrophy, secondary bacterial infection, impaired mobility, and reduced quality of life.

The current onychomycosis treatment landscape includes oral antifungal therapy, topical antifungal solutions and lacquers, mechanical debridement, device-assisted approaches such as laser-based therapy in selected settings, and combination regimens designed to improve nail penetration and clinical outcomes. Oral terbinafine and itraconazole remain widely used systemic options, while topical agents are important for mild-to-moderate disease, patients with contraindications to systemic therapy, and long-term maintenance strategies. Demand is shaped by the need for safer therapies, shorter treatment durations, better mycological cure rates, lower recurrence, and improved patient compliance.

Transformative Shifts in the Onychomycosis Treatment Landscape

The onychomycosis treatment landscape is being reshaped by a stronger emphasis on diagnostic certainty, patient-centered care, and resistance-aware prescribing. Traditional empirical treatment is increasingly being complemented by confirmatory testing, including potassium hydroxide microscopy, fungal culture, histopathology with periodic acid-Schiff staining, and molecular diagnostic methods where available. This shift is important because nail dystrophy can mimic psoriasis, trauma-related nail changes, lichen planus, and other non-fungal disorders, making accurate diagnosis essential before initiating prolonged antifungal treatment.

Therapeutic strategies are also evolving toward individualized regimens based on infection severity, nail matrix involvement, comorbidities, drug interaction risk, hepatic safety considerations, and patient preference. Combination therapy, pairing oral antifungals with topical agents or debridement, is increasingly used in difficult-to-treat cases to enhance drug access to infected nail tissue. At the same time, growing awareness of recurrence has expanded interest in foot hygiene, shoe disinfection, tinea pedis management, nail care education, and maintenance therapy. These shifts indicate a broader movement from episodic infection treatment toward long-term fungal disease management.

Cumulative Impact of Artificial Intelligence on Onychomycosis Care

Artificial intelligence is beginning to influence onychomycosis treatment through diagnostic support, image-based triage, workflow optimization, and adherence management. AI-enabled dermatology tools can assist clinicians by analyzing nail images for patterns consistent with fungal infection, although confirmatory laboratory testing remains necessary because clinical appearance alone is not sufficiently specific. In teledermatology and digital podiatry workflows, AI can help prioritize cases, identify high-risk patients, and support remote monitoring of nail improvement over the long treatment period required for toenail regrowth.

AI also has potential to improve treatment selection by integrating patient history, medication profiles, comorbidity data, liver function considerations, and prior antifungal exposure into decision-support frameworks. In pharmaceutical and clinical research settings, machine learning can support antifungal discovery, formulation optimization, drug repurposing assessment, and analysis of real-world treatment persistence. The cumulative impact of AI is therefore most meaningful when it augments clinical judgment, improves diagnostic pathways, reduces unnecessary antifungal exposure, and helps patients remain adherent during therapy that may require months of consistent use.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific demonstrates significant need for onychomycosis treatment due to large aging populations, high diabetes burden in several countries, humid climates that favor fungal growth, and rising access to dermatology and podiatry services in urban centers. Countries across the region are also seeing increased use of telemedicine and retail pharmacy access, which can improve early consultation but may also heighten the need for diagnostic stewardship to reduce inappropriate antifungal use. North America is characterized by established dermatology, podiatry, and primary care pathways, with treatment demand supported by a large older adult population, high prevalence of diabetes, and broad awareness of nail health and foot care. Access to prescription topical and oral therapies, diagnostic testing, and specialist care is comparatively strong, while safety monitoring and drug interaction management remain important in systemic antifungal use.

Latin America faces a mixed landscape in which warm climates, occupational exposure, sports participation, and variable access to specialist dermatology shape treatment patterns. Public and private healthcare differences influence diagnostic confirmation and therapy selection, making affordable antifungal access and patient education important. Europe benefits from mature clinical guidelines, strong primary care referral systems in many countries, and heightened attention to antimicrobial stewardship and evidence-based prescribing. The Middle East shows rising demand linked to diabetes prevalence, hot climates, footwear practices, and expanding private healthcare infrastructure, while Africa presents a high-need environment where limited access to laboratory diagnostics, dermatology specialists, and consistent antifungal supply can delay appropriate care. Across all regions, improved diagnosis, adherence support, and recurrence prevention are central to better onychomycosis treatment outcomes.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries present a diverse onychomycosis treatment environment shaped by tropical humidity, rapid urbanization, expanding pharmacy networks, and uneven access to dermatology specialists across urban and rural settings. Public health priorities often focus on communicable and chronic diseases, yet the overlap between fungal nail infections, diabetes care, and foot health creates opportunities to integrate onychomycosis screening into broader primary care and podiatric services. GCC countries show increasing relevance for onychomycosis management due to high diabetes prevalence, strong private healthcare adoption, medical tourism activity in selected markets, and demand for advanced dermatology services, including device-assisted and cosmetic-adjacent nail care solutions.

The European Union is distinguished by evidence-led clinical practice, pharmacovigilance, and growing attention to antifungal resistance and responsible prescribing. Harmonized regulatory oversight supports consistent quality expectations for antifungal therapies, while national reimbursement differences influence patient access. BRICS countries collectively represent broad treatment diversity, ranging from highly developed urban specialty care to resource-constrained settings where laboratory confirmation and specialist availability remain limited. G7 markets generally have advanced healthcare infrastructure, strong diagnostic capacity, and greater adoption of digital health tools, supporting integrated care pathways for chronic and recurrent nail fungal infections. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where military, occupational, and athletic foot health considerations reinforce the importance of prevention, early diagnosis, and treatment adherence in populations exposed to shared footwear environments, communal facilities, and repeated nail trauma.

Key Country Insights Across Major Onychomycosis Treatment Markets

The United States has a mature onychomycosis treatment environment supported by extensive dermatology and podiatry networks, high diabetes prevalence, and widespread access to oral and topical antifungal therapies, though cost, adherence, and recurrence remain persistent barriers. Canada shows similar clinical priorities, with strong primary care involvement and attention to safety monitoring in older adults and patients using multiple medications. Mexico and Brazil face substantial need due to climate, population size, diabetes burden, and variable access to specialist care, making accurate diagnosis, affordability, and pharmacy-based education especially important.

In Europe, the United Kingdom, Germany, France, Italy, and Spain generally benefit from established healthcare systems and evidence-based prescribing, with systemic antifungal selection shaped by hepatic safety, drug interaction risk, and diagnostic confirmation practices. Russia presents a broad care landscape in which urban centers offer greater access to dermatology services, while regional disparities can affect diagnostic and treatment continuity. In Asia-Pacific, China and India have large patient populations, rising diabetes prevalence, humid regional climates, and expanding digital health ecosystems that can support awareness and remote consultation, although quality-assured diagnosis and adherence remain essential. Japan's aging population increases the clinical relevance of toenail onychomycosis, particularly in mobility, foot care, and geriatric health contexts. Australia combines high awareness of dermatology services with outdoor lifestyles and sports-related nail trauma as contributing factors, while South Korea's advanced digital health infrastructure, strong dermatology access in urban areas, and high consumer attention to nail appearance support early presentation and treatment engagement.

Actionable Recommendations for Onychomycosis Treatment Industry Leaders

Industry leaders should prioritize evidence-based onychomycosis treatment pathways that combine accurate diagnosis, appropriate antifungal selection, patient education, and recurrence prevention. Strengthening access to confirmatory testing is essential, particularly because nail dystrophy is not always fungal and unnecessary antifungal exposure can create avoidable safety and stewardship concerns. Treatment programs should incorporate clear guidance on oral therapy monitoring, topical application technique, expected nail regrowth timelines, and the importance of completing therapy despite slow visible improvement.

Stakeholders should also invest in patient adherence tools, teledermatology support, digital monitoring, and integrated foot care programs for high-risk groups such as people with diabetes, older adults, immunocompromised individuals, athletes, and patients with recurrent tinea pedis. Product development should focus on improved nail penetration, shorter regimens, lower systemic exposure, and formulations that are easy to apply consistently. Education for pharmacists, primary care providers, podiatrists, and dermatologists can improve early recognition and referral, while public awareness initiatives should emphasize hygiene, footwear management, treatment persistence, and relapse prevention.

Research Methodology for Onychomycosis Treatment Insights

This executive summary is developed through a structured secondary research methodology using verified clinical, regulatory, and public health sources. The assessment draws on dermatology and infectious disease guidelines, peer-reviewed medical literature, pharmacology references, public health data on diabetes and aging populations, and established clinical knowledge regarding antifungal treatment, diagnostic methods, recurrence, and risk factors. Regional, group, and country insights are synthesized from documented healthcare infrastructure characteristics, disease risk patterns, demographic indicators, and access considerations relevant to onychomycosis diagnosis and treatment.

The methodology emphasizes data validation through source triangulation, clinical consistency checks, and exclusion of unsupported claims. Insights are framed qualitatively to avoid market estimation, market sizing, market share, or forecasting. The analysis focuses on disease burden drivers, treatment pathways, healthcare access, diagnostic practices, safety considerations, and technology-enabled care trends. This approach supports an evidence-based view of the onychomycosis treatment landscape while maintaining relevance for strategic decision-making, discoverability, and industry-specific content requirements.

Conclusion: Advancing Evidence-Based Onychomycosis Treatment

Onychomycosis treatment is moving toward more precise, patient-centered, and technology-supported care. Accurate diagnosis remains the foundation of effective management, while oral antifungals, topical therapies, debridement, and combination approaches continue to serve different patient needs based on infection severity, safety profile, and adherence capacity. The growing role of AI, telehealth, and digital adherence tools can improve care delivery, but these technologies are most valuable when integrated with laboratory confirmation and clinician oversight.

Across regions and country groups, the strongest opportunities lie in improving diagnostic access, strengthening antifungal stewardship, supporting high-risk populations, and reducing recurrence through long-term foot and nail health strategies. Industry participants that align innovation with clinical evidence, safety, affordability, and patient convenience will be best positioned to support better outcomes in fungal nail infection management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Onychomycosis Treatment Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Azoles
  • 7.3. Allylamines

8. Onychomycosis Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Topical Therapy
  • 8.3. Oral Therapy
  • 8.4. Combination Therapy

9. Onychomycosis Treatment Market, by Disease Severity

  • 9.1. Introduction
  • 9.2. Mild
  • 9.3. Moderate
  • 9.4. Severe

10. Onychomycosis Treatment Market, by Formulation

  • 10.1. Introduction
  • 10.2. Cream
  • 10.3. Gel
  • 10.4. Nail Lacquer
  • 10.5. Solution
  • 10.6. Tablet Capsule

11. Onychomycosis Treatment Market, by Disease Severity

  • 11.1. Introduction
  • 11.2. Mild To Moderate
  • 11.3. Recurrent
  • 11.4. Severe

12. Onychomycosis Treatment Market, by Age Group

  • 12.1. Introduction
  • 12.2. 18 To 65 Years
  • 12.3. Above 65 Years
  • 12.4. Below 18 Years

13. Onychomycosis Treatment Market, by Treatment Setting

  • 13.1. Introduction
  • 13.2. Home Care
  • 13.3. Hospital Inpatient
  • 13.4. Outpatient Clinic

14. Onychomycosis Treatment Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Offline
  • 14.3. Online

15. Onychomycosis Treatment Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. Europe
  • 15.3. North America
  • 15.4. Latin America
  • 15.5. Africa
  • 15.6. Middle East

16. Onychomycosis Treatment Market, by Group

  • 16.1. NATO
  • 16.2. G7
  • 16.3. BRICS
  • 16.4. European Union
  • 16.5. ASEAN
  • 16.6. GCC

17. Onychomycosis Treatment Market, by Country

  • 17.1. China
  • 17.2. United States
  • 17.3. Japan
  • 17.4. India
  • 17.5. Germany
  • 17.6. United Kingdom
  • 17.7. Australia
  • 17.8. France
  • 17.9. South Korea
  • 17.10. Italy
  • 17.11. Canada
  • 17.12. Russia
  • 17.13. Brazil
  • 17.14. Mexico
  • 17.15. Spain

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2025
  • 18.2. FPNV Positioning Matrix, 2025
  • 18.3. Market Concentration Analysis, 2025
    • 18.3.1. Concentration Ratio (CR)
    • 18.3.2. Herfindahl Hirschman Index (HHI)
  • 18.4. Recent Developments & Impact Analysis, 2025
  • 18.5. Product Portfolio Analysis, 2025
  • 18.6. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. Astellas Pharma Inc.
  • 19.3. Aurobindo Pharma Limited
  • 19.4. Bausch Health Companies Inc.
  • 19.5. Bayer AG
  • 19.6. Cipla Limited
  • 19.7. Dr. Reddy's Laboratories Ltd.
  • 19.8. Eisai Co., Ltd.
  • 19.9. Galderma S.A.
  • 19.10. GlaxoSmithKline plc
  • 19.11. Glenmark Pharmaceuticals Ltd.
  • 19.12. Janssen Pharmaceuticals, Inc.
  • 19.13. Kaken Pharmaceutical Co., Ltd.
  • 19.14. Lupin Limited
  • 19.15. Merck & Co., Inc.
  • 19.16. Moberg Pharma AB
  • 19.17. Novartis AG
  • 19.18. Pfizer Inc.
  • 19.19. Sandoz International GmbH
  • 19.20. Sanofi S.A.
  • 19.21. Sun Pharmaceutical Industries Ltd.
  • 19.22. Teva Pharmaceutical Industries Ltd.
  • 19.23. Wockhardt Limited
  • 19.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 29. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLYLAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLYLAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLYLAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TOPICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOPICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOPICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NAIL LACQUER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NAIL LACQUER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NAIL LACQUER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TABLET CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TABLET CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TABLET CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MILD TO MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MILD TO MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MILD TO MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RECURRENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECURRENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RECURRENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL 18 TO 65 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL 18 TO 65 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL 18 TO 65 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ABOVE 65 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ABOVE 65 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ABOVE 65 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BELOW 18 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BELOW 18 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BELOW 18 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OUTPATIENT CLINIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OUTPATIENT CLINIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OUTPATIENT CLINIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 218. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 256. AUSTRALIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 272. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 274. SOUTH KOREA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 330. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025